Peng Jianhong, Ou Qingjian, Pan Zhizhong, Zhang Rongxin, Zhao Yujie, Deng Yuxiang, Lu Zhenhai, Zhang Lin, Li Caixia, Zhou Yaxian, Guo Jian, Wan Desen, Fang Yujing
Department of Colorectal Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, China.
Department of Experimental Research, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South ; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, China.
Aging (Albany NY). 2018 Aug 2;10(8):1921-1931. doi: 10.18632/aging.101512.
Since early diagnosis is very important for treating CRC, we decided to detect peripheral serum canopy fibroblast growth factor signaling regulator 2 (CNPY2) isoform 2 to verify its diagnostic value for CRC patients. Serum samples were collected from 430 CRC patients and 201 healthy controls. Enzyme-linked immunosorbent assay (ELISA) detection kits for CNPY2 isoform 2 were generated and then applied to measure serum CNPY2 isoform 2 concentrations. Serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were also measured. The median serum CNPY2 isoform 2 concentrations in all CRC patients were significantly higher than those in the healthy control group (all P<0.001). Those with stage I CRC presented the highest area under the receiver operating characteristic curve (AUC) for CNPY2 isoform 2 [0.707, 95% confidence interval (CI): 0.649-0.765, P<0.001]. The diagnostic efficiency of the combination of CNPY2 isoform 2, CEA and CA19-9 was significantly higher than that of each biomarker detected separately (all P<0.0167). Serum CNPY2 isoform 2 may be a valuable biomarker for the early detection of CRC and presents an improvement in the diagnostic efficiency by combination of CEA and CA19-9.
由于早期诊断对结直肠癌的治疗非常重要，我们决定检测外周血清冠层成纤维细胞生长因子信号调节因子2（CNPY2）亚型2，以验证其对结直肠癌患者的诊断价值。收集了430例结直肠癌患者和201例健康对照者的血清样本。制备了用于CNPY2亚型2的酶联免疫吸附测定（ELISA）检测试剂盒，然后用于测量血清CNPY2亚型2的浓度。还检测了血清癌胚抗原（CEA）和糖类抗原19-9（CA19-9）。所有结直肠癌患者血清CNPY2亚型2的中位浓度显著高于健康对照组（所有P<0.001）。I期结直肠癌患者中CNPY2亚型2的受试者工作特征曲线下面积（AUC）最高[0.707，95%置信区间（CI）：0.649-0.765，P<0.001]。CNPY2亚型2、CEA和CA19-9联合检测的诊断效率显著高于单独检测每种生物标志物的诊断效率（所有P<0.0167）。血清CNPY2亚型2可能是结直肠癌早期检测的有价值生物标志物，并且通过与CEA和CA19-9联合可提高诊断效率。
